Search PubMed⌕ Search

Biomedical subjects

M Roger

Publications and source records attributed to M Roger.

At least 271 records · Page 15Linked to original sources

The GnRH test in idiopathic hemochromatosis.

In 10 patients, 8 males and 2 females, suffering from idiopathic hemochromatosis (IH), the gonadotropic function has been studied using the GnRH test (iv administration of 100 micrograms) to make precise the pathogenesis of their hypogonadism. The FSH and LH mean basal levels were low and almost unaffected by GnRH (p < 0.001 at each time value when compared to controls). The hypogonadism often observed during the course of IH seems to be hypogonadotropic. Various factors could be responsible for this disturbance. The exact site of the lesion, whether hypothalamic or hypophyseal, remains unknown.

17-Ketosteroids↗

Description of a large projection from the mesodiencephalic junction to the rostral red nucleus. An anatomical study in the rat and in the cat.

Horseradish peroxidase (HRP) or wheat germ agglutinin conjugated to HRP (WGA-HRP) were deposited in the rostral pole (Rpc) of the red nucleus in 6 rats and 5 cats. In the rat, a zone of dense retrograde cell labeling and of diffuse axonal labeling occurred in the sub-pretectal area, a region which corresponds to the posterior thalamic nucleus (PT) of Bold et al. (Brain Research, 12 (1984) 521-527). In the cat, a similar retrograde and anterograde pattern of labeling was observed. The labeled area extended from the deep pretectum up to the diencephalon above the dorsomedial aspect of the ventral posterior thalamic nucleus. In a second set of experiments, 14 rats received a tracer injection (HRP, WGA-HRP or Phaseolus vulgaris-leucoagglutinin) in the sub-pretectal area. The resultant pattern of labeling consisted in a heavy anterograde terminal labeling within the Rpc of the red nucleus. Sparse retrograde cell labeling also occurred in the Rpc.

Animals↗

The relationship between alertness and sleep in a population of 769 elderly insomniacs with and without treatment with zolpidem.

The sleep and life rhythms of 769 insomniacs aged more than 65 years were recorded during a period of 3 months before and after a treatment with 5 mg or 10 mg zolpidem per day during 27 days. The patients were selected by general practitioners throughout France: all had been suffering from insomnia for more than 3 weeks and were included in the study whether they had or had not been treated for these sleep disturbances. The evaluation of sleep and life rhythms was made by both the practitioners and the patients during 3 months. A single course of 5 or 10 mg per day of zolpidem during 27 days seemed sufficient to improve sleep parameters and increase alertness in a large percentage of insomniacs, thus establishing a clear relationship between sleep and alertness in the elderly.

Journal Article↗

Evaluation of PS beta 1G and other tumor markers in germ cell tumors of the testis.

Pregnancy Specific beta 1 Glycoprotein (PS beta 1G), human choriogonadotropin (hCG), alpha foeto protein (AFP) and Carcino Embryonic Antigen (CEA) were assayed in 58 patients with active germ cell tumors and 20 patients in complete clinical and radiological remission. The markers were negative in all the cases in remission as well as in one case of pure teratoma. The positivity rate of the four markers together is 75%, which is better than for any marker alone. All the markers except AFP seem ubiquitous with respect to the histological classification. The highest positivity rate is obtained for hCG in all the histological types. PS beta 1G is related to hCG but its positivity rate is quite lower. AFP is mainly related to embryonal carcinoma but can be associated with any type of tumor except seminoma. CEA is less frequently positive, always associated with other markers and seems therefore useless for the diagnosis of germ cell tumors.

Carcinoembryonic Antigen↗

Reversible effects of long-term treatment with D-Trp6-LH-RH-microcapsules on pituitary-gonadal axis, spermatogenesis and prostate morphology in adolescent and adult dogs.

The effect of long term treatment with D-Trp6-LH-RH in microcapsules (GnRH-A) on pituitary gonadal axis was studied in a adolescent and adult Fox-terrier dogs. They received intramuscularly 50 micrograms/GnRH-A/kg, on day 1 and 21 and every 4 weeks thereafter. Three adult dogs received 4 injections. cLH, cFSH and T levels were undetectable on day 7. Detectable then normal levels occurred 60 and 90 days respectively after the last injection on day 77. Testis thickness was respectively 22.1 +/- 0.8 mm and 16.3 +/- 0.8 mm on days 0 and 77; initial values were observed 90 days later. Spermatozoa disappeared from the ejaculate on day 21 in 2 dogs; reappearance and complete recovery were observed on days 161-175 and 252 respectively. Histological findings showed on day 91 atrophic lesions of testis and prostate and spermatogonia were present in all seminiferous tubules. After recovery a normal histological appearance was noticed. Three adolescent 29 weeks old dogs received 14 injections, the last one on day 357. cLH, cFSH and T levels were undetectable only from day 105. Testis thickness were respectively 15.8 +/- 0.7 mm, 18.1 +/- 0.7 mm, 12.5 +/- 0.3 mm and 21.4 +/- 0.7 mm on day 0, 21, 357 and 490. Initially, no spermatozoa were present in the ejaculates, they appeared in 2 dogs after 2 months for 20 to 40 days then disappeared until day 449. Normal semen characteristics were observed in all three dogs on day 581. Histological findings on day 371 were comparable to those observed in the adult dogs. This study demonstrates that longterm treatment with D-Trp6-LH-RH in microcapsules leads to a reversible inhibition of spermatogenesis in dogs. The delayed response in adolescent dogs might be due to a transient resistance to therapy related to.

Animals↗

Anatomical and functional characteristics of fetal neocortex transplanted into the neocortex of newborn or adult rats.

In humans, the cerebral cortex can be affected by a variety of diseases (vascular, traumatic, neurodegenerative, etc.) and, therefore, several experimental studies have been undertaken to determine to what extent transplantation of cortical neurons could prove a useful treatment for cerebral cortical damage. The purpose of this review is to give an evaluation of the different attempts of neocortical tissue transplantation which have been undertaken, mostly in rodents, during the last decade. First, we examine the functional effects of neocortical tissue transplantation in various tasks designed to assess different aspects of behavior depending upon the localization and function of the cortical area under investigation. Second, a variety of mechanisms have been proposed by which the graft would improve host behavioral capacities. Two of these are considered in this review: trophic action on the host brain and reconstruction of cortical circuitry. Most behavioral studies in rodents seem to indicate that better synaptic integration and larger functional improvements are achieved when the embryonic neocortical tissue is transplanted into immature host neocortex, i.e. in newborn recipients. Transplantation of embryonic neocortex into an adult damaged cortex seems to provide only partial functional improvement. In adult hosts, the synaptic integration of the transplanted neurons is incomplete since, in most instances, long distance projections are not re-established. It seems, therefore, that transplantation of embryonic cortex into adult hosts would prove a useful therapeutic method only if there is a possibility of neutralizing the growth inhibitory factors of the mature host CNS.

Animals↗

[Myasthenia in the aged: a case with unusually late onset].

BACKGROUND: Myasthenia is an uncommon autoimmune condition that can occur at any age. Peak frequency is seen around the age of 65 years. We report a case with a particularly late onset and discuss the particular conditions of myasthenia in the elderly subject. CASE REPORT: A 97-year-old patient was hospitalized for dysphonia and dysphagia associated with exercise-induced dyspnea. The general picture suggested generalized myasthenia confirmed by the electromyography exploration and a positive anticholinesterase test. Treatment with acetylcholinesterase inhibitor was effective although cure was incomplete. Further improvement was obtained with immunosuppressor therapy using azathioprine. DISCUSSION: The clinical presentation of very late onset myasthenia differs little from that in younger subjects excepting the very high frequency of brain stem involvement in the initial presentation. Diagnosis may however be more difficult as other conditions are more easily taken to be the causal element. Thus, for the elderly patient, the real problem is to envisage the diagnosis of myasthenia. Positive diagnosis is based on the same criteria as in younger subjects. Clinicians should be aware of the possibility of myasthenia in the geriatric population as specific treatment can improve functional prognosis with satisfactory efficacy.

Age Factors↗

[Plasma dehydroepiandrosterone concentrations in normal boys and in those with growth retardation].

Radioimmunoassay of plasma DHA in 179 boys 2 to 16 years old has allowed assessment of normal values (mean and 95% confidence limits) increasing with age on a log DHA/age relationship. Plasma DHA was normal in 58 cases of male idiopathic growth retardation and 40 boys with delayed adolescence. It was significantly increased in 42 obese boys. DHA levels were normal in 10 hypopituitary dwarfs with isolated GH deficiency, and significantly decreased in 24 others with multiple pituitary deficiencies. In pituitary dwarfism, a lowered DHA level may be a reliable index of ACTH deficiency, and may be of importance for evaluation of therapeutic programmes.

Adolescent↗

[Congenital adrenal hyperplasia due to blockade of 3-beta-hydroxysteroid dehydrogenase].

Five cases of congenital 3 beta-hydroxysteroid deshydrogenase deficiency in children are reported: four boys with perineal posterior hypospadias and one girl with clitoromegaly. The salt losing syndrome was clinically overt in only three patients. The main biological character was the very high level of plasma dehydroepiandrosterone (DHA) with an elevated DHA/delta 4 androstenedione ratio. The 17 alpha-OH progesterone, though in normal biosynthesis of glucocorticoids being produced beyond the enzymatic block, was raised, but this apparently paradoxical observation may assist making the diagnosis. Deficient production of testosterone was demonstrated in the prepubertal boys by absence of postnatal rise in plasma testosterone or a decreased reponse of plasma testosterone to chorionic gonadotrophin. It is concluded that deficiency of 3 beta-hydroxysteroid deshydrogenase, now easily recognizable with the use of plasma steroids radioimmunoassay, is probably less rare than was apparent with the use of urinary steroid estimations.

3-Hydroxysteroid Dehydrogenases↗

[Plasma androgens in boys from birth to adolescence (author's transl)].

Plasma testosterone, androstenedione, dehydroepiandrosterone and dehydroepiandrosterone-sulfate were measured by radioimmunoassay in 222 normal boys aged 1 hour to 18 years and 40 normal men aged 20 to 40 years. Three periods of high testosterone levels were observed in boys during extra-uterine life: first day (mean level 12 nmol/l), from the 12th to the 119th day (9 nmol/l) and from 13 years onwards in pubertal boys; the highest values were reached between 20 and 40 years (18 nmol/l). Androstenedione curve exhibited three coincident high concentrations phases: mean level at birth 8.7 nmol/l, and from 12th to 119th day 2.6 nmol/l. The lowest values were observed between 2 and 4 years; then a progressive increase occured up to adult age levels: 3.5 nmol/l. Dehydroepiandrosterone mean level was high at birth (20 nmol/l) then decreased slowly, either regularly or with a rebound during the 2nd month, a minimum being reached between 2 and 4 years (0.28 nmol/l). It increased thereafter exponentially up to adult levels reached after the age of 16 years (14 nmol/l). Dehydroepiandrosterone-sulfate mean level decreased regularly from birth to the second year, then its curve paralleled the dehydroepiandrosterone curve.

Adolescent↗

Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis.

Eight menstrually cycling women with proven endometriosis were treated with a delayed-release preparation of the superactive agonist D-Trp-6-LH-RH in biodegradable microcapsules, administered intramuscularly at intervals of 16 to 36 days for a period of 3 to 5 months. After the first injection which caused a transient stimulatory response, a sustained hypogonadal state, characterized by an estradiol (E2) level less than 50 pg/mL, was induced in all patients by day +14.7 (range 7.19). Subsequent injections caused no more stimulation, but a continuous decrease in E2 levels was observed. In all patients, E2 levels fell to zero after the second or third injection. Gonadotropins remained in the normal range throughout the course of treatment. Hot flashes and severe dyspareunia (related to vaginal dryness) were the main side effects. Resumption of normal pituitary-ovarian activity was documented in all patients after the last injection; the end of the hypogonadal state, ovulation and menses, occurred on days 41 (range 32-59), 58 (range 51-64) and 70 (range 65-76), respectively. All patients showed a clinical improvement. Our results demonstrate that a long-lasting, reversible hypogonadism can be induced in cyclic women by intramuscular injections of D-Trp-6-LH-RH microcapsules at monthly intervals. This simple and convenient treatment should be useful in treating endometriosis and other conditions.

Adult↗

[Responses of somatotropin to stimuli after brief administration of estradiol in short children].

Ethinyl estradiol has been administered orally, 100 micrograms per day during three days, to enhance the growth hormone (GH) response to usual pharmacological stimuli. 102 prepubertal short patients aged 2 to 17 years with height between 2 to 6 SD below the mean, were studied. Human growth hormone (hGH) treatment was given only to those patients whose GH response was still below 10 ng/ml after estradiol. Under hGH treatment, their growth rate increased twofold, as much in patients with partial GH deficiency as in those with complete GH deficiency. It is concluded that the lack of GH response after estradiol priming contributes to the assessment of the indication for treatment with hGH. However, since it has not been possible to give this treatment to very short children whose GH response became normal after priming, this study does not allow to preclude the effect of hGH in such conditions. Thus estradiol priming must not be included among the practical criteria leading to therapeutic decision in doubtful cases.

Adolescent↗